Efficacy of edaravone in cardioembolic stroke
Efficacy of edaravone in cardioembolic stroke
复制标题
DOI：
10.2169/internalmedicine.45.1423
复制
发表时间：
2006-01-01
影响因子：
1.2
通讯作者：
Uchino, Makoto
中科院分区：
文献类型：
--
作者：
Inatomi, Yuichiro;Takita, Tomohiro;Uchino, Makoto
目的观察依达拉奉治疗心源性脑卒中的疗效（艾德组，n=141）7天，并与类似患者的历史对照队列进行回顾性比较对照组114例。（第0天和第10天之间），定义为美国国立卫生研究院卒中量表（NIHSS）的变化，在艾德组中，轻度患者（入院时NIHSS评分为7分）的NIHSS变化率高于对照组（NIHSS评分变化分别为+2 vs.-2，p=0.013）。在中度至重度（NIHSS > 7）患者中未观察到类似的疗效。独立患者（改良兰金量表2）在发病后6个月在艾德中的发生率可能低于对照组（28% vs 41%; p=0.066）。艾德组的其他临床结局与对照组无显著性差异。结论依达拉奉可能仅对轻度心源性栓塞性脑卒中患者有效。
Objective We investigated the efficacy of edaravone in patients with cardioembolic stroke.Methods Cardioembolic stroke patients were treated with drip intravenous infusion of edaravone (ED group, n=141) for 7 days, and were retrospectively compared with a historical-controlled cohort of similar patients (control group, n= 114).Results Early improvement (between day 0 and day 10), defined as change in National Institutes of Health Stroke Scale (NIHSS), was seen more frequently in mild patients (NIHSS on admission 7) among the ED group than in the control group (change in NIHSS +2 vs. -2, respectively, p=0.013). Similar efficacy was not seen in the moderate to severe (NIHSS > 7) patients. Independent patients (modified Rankin Scale 2) 6 months after the onset were likely to be less frequent in the ED than the control group (28% versus 41%; p=0.066). Other clinical outcomes in the ED group were not significantly different from those in the control group.Conclusion The results suggest that edaravone may only be effective in mild patients with cardioembolic stroke.